North Star Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-200
| Closed | -$1.24K | – | 1190 |
|
|
2024
Q2 | $1.24K | Hold |
200
| – | – | ﹤0.01% | 1081 |
|
|
2024
Q1 | $1.02K | Buy |
+200
| New | +$1.02K | ﹤0.01% | 1156 |
|
|
2023
Q2 | – | Sell |
-20,000
| Closed | -$167K | – | 1295 |
|
|
2023
Q1 | $167K | Sell |
20,000
-347,300
| -95% | -$2.9M | 0.01% | 450 |
|
|
2022
Q4 | $4.22M | Sell |
367,300
-74,600
| -17% | -$856K | 0.37% | 66 |
|
|
2022
Q3 | $5.57M | Hold |
441,900
| – | – | 0.55% | 42 |
|
|
2022
Q2 | $4.68M | Sell |
441,900
-1,500
| -0.3% | -$15.9K | 0.43% | 59 |
|
|
2022
Q1 | $7.21M | Sell |
443,400
-6,400
| -1% | -$104K | 0.56% | 38 |
|
|
2021
Q4 | $6.23M | Buy |
449,800
+6,900
| +2% | +$95.6K | 0.44% | 53 |
|
|
2021
Q3 | $6.36M | Buy |
442,900
+6,210
| +1% | +$89.2K | 0.52% | 48 |
|
|
2021
Q2 | $6.9M | Buy |
436,690
+900
| +0.2% | +$14.2K | 0.55% | 44 |
|
|
2021
Q1 | $4.43M | Buy |
435,790
+135,600
| +45% | +$1.38M | 0.42% | 65 |
|
|
2020
Q4 | $2.24M | Buy |
300,190
+125,190
| +72% | +$932K | 0.23% | 109 |
|
|
2020
Q3 | $601K | Buy |
175,000
+135,000
| +338% | +$464K | 0.07% | 224 |
|
|
2020
Q2 | $191K | Buy |
+40,000
| New | +$191K | 0.02% | 332 |
|